ACOR:NSD-Acorda Therapeutics, Inc (USD)

COMMON STOCK | Biotechnology | NSD

Last Closing Price

USD 0.87

Change

0.00 (0.00)%

Market Cap

USD 0.05B

Volume

0.65M

Average Target Price

USD 5.80 (+564.60%)
Average Analyst Rating

Verdict

Fundamental Analysis

Verdict

About

Acorda Therapeutics, Inc., a biopharmaceutical company, develops and commercializes therapies for neurological disorders in the United States. The company markets Ampyra (dalfampridine), an oral drug to improve walking in patients with multiple sclerosis (MS); and Selincro, an orally administered drug for the treatment of alcohol dependence in Europe. It also markets Ampyra as Fampyra in Europe, Asia, and the Americas. In addition, the company develops Inbrija for the treatment of OFF periods in Parkinson's disease; an inhaled triptan (zolmitriptan) for acute treatment of migraine by using the ARCUS drug delivery technology; SYN120, which is completed Phase II clinical trial to treat Parkinson's disease-related dementia; and BTT1023 (timolumab) for primary sclerosing cholangitis. Further, it develops rHIgM22, which has completed Phase I clinical trial for the treatment of MS; and Cimaglermin alfa that is in Phase Ib clinical trial for heart failure patients. The company has collaboration and license agreement with Biogen Inc. for the development and commercialization of Ampyra. Acorda Therapeutics, Inc. was founded in 1995 and is headquartered in Ardsley, New York.

Technical Indicators

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2020-04-04 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
VRTX Vertex Pharmaceuticals Incorpo..

N/A

USD62.78B 52.76 N/A
REGN Regeneron Pharmaceuticals, Inc

N/A

USD54.87B 26.90 N/A
SGEN Seattle Genetics, Inc

N/A

USD20.11B N/A N/A
ALXN Alexion Pharmaceuticals, Inc

N/A

USD19.94B 7.85 N/A
INCY Incyte Corporation

N/A

USD16.71B 33.64 N/A
BMRN BioMarin Pharmaceutical Inc

N/A

USD15.04B N/A 33,757.20
GMAB Genmab A/S

N/A

USD13.41B N/A N/A
BNTX BioNTech SE

N/A

USD12.91B N/A N/A
GLPG Galapagos NV

N/A

USD12.44B 72.40 N/A
ALNY Alnylam Pharmaceuticals, Inc

N/A

USD11.78B N/A N/A

ETFs Containing ACOR

Symbol Name Weight Mer Price(Change) Market Cap

N/A

Market Performance

  Market Performance vs.
Industry/Classification (Biotechnology)
Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -57.22% 12% F 14% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -57.22% 12% F 13% F
Trailing 12 Months  
Capital Gain -93.42% 2% F 2% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -93.42% 2% F 2% F
Trailing 5 Years  
Capital Gain -97.40% 16% F 6% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -97.40% 14% F 6% F
Average Annual (5 Year Horizon)  
Capital Gain -27.83% 21% F 10% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -27.83% 21% F 9% F
Risk Return Profile  
Volatility (Standard Deviation) 41.54% 57% F 31% F
Risk Adjusted Return -67.00% 25% F 13% F
Market Capitalization 0.05B 26% F 28% F
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Biotechnology)
Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio 16.50 41% F 49% F
Price/Book Ratio 0.15 100% A+ 95% A
Price / Cash Flow Ratio -0.37 13% F 62% D-
EV/EBITDA -2.10 47% F 65% D
Management Effectiveness  
Return on Equity -59.16% 57% F 20% F
Return on Invested Capital -15.53% 79% C+ 28% F
Return on Assets -6.94% 88% B+ 30% F
Debt to Equity Ratio 70.22% 23% F 32% F
Technical Ratios  
Short Ratio 7.46 25% F 16% F
Short Percent 50.75% 1% F 6% F
Beta 1.64 44% F 20% F
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Underpriced compared to book value

The stock is trading low compared to its peers on a price to book value basis and is in the top quartile. It may be underpriced but do check its financial performance to make sure there is no specific reason.

Superior capital utilization

The company management has delivered better return on invested capital in the most recent 4 quarters than its peers, placing it in the top quartile.

Superior return on assets

The company management has delivered better return on assets in the most recent 4 quarters than its peers, placing it in the top quartile.

High Gross Profit to Asset Ratio

This stock is in the top quartile compared to its peers on Gross Profit to Asset Ratio. This is a popular measure among value investors for showing superior returns in the long run.

What to not like:
Low market capitalization

This is among the smaller entities in its sectors with below median market capitalization. That may make it less stable in the long run unless it has a unique technology or market which can help it grow or get acquired in future.

Poor risk adjusted returns

This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.

Below median dividend returns

The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.

Overpriced compared to earnings

The stock is trading high compared to its peers on a price to earning basis and is above the sector median.

Higly leveraged

The company is in the bottom half compared to its sector peers on debt to equity and is highly leveraged. However, do check the news and look at its sector and management statements. Sometimes this is high because the company is trying to grow aggressively.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.

Negative free cash flow

The company had negative total free cash flow in the most recent four quarters.

Low Earnings Growth

This stock has shown below median earnings growth in the previous 5 years compared to its sector

Low Revenue Growth

This stock has shown below median revenue growth in the previous 5 years compared to its sector